Protalix BioTherapeutics Inc.

Protalix BioTherapeutics Inc.

PLX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$257.17M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Protalix BioTherapeutics Inc.Protalix BioTherapeutics Inc.11.7-26%3.10.1
$6.00

Target Price by Analysts

96.7% upsideProtalix BioTherapeutics Target Price DetailsTarget Price
$-2.48

Current Fair Value

181.3% downside

Overvalued by 181.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$257.17 Million
Enterprise Value$244.28 Million
Earnings per Share$-0.08
Beta0.01
Outstanding Shares80,455,731

Return

Return on Equity25.51%ROE
Return on Assets17.38%
Return on Invested Capital24.49%

Valuation & Multiples

P/E Ratio11.72P/E Ratio
PEG17.19PEG
Price to Sales3.05Price to Sales
Price to Book Ratio3.05Price to Book Ratio
Enterprise Value to Revenue2.88
Enterprise Value to EBIT11.33
Enterprise Value to Net Income11
Total Debt to Enterprise0.04
Debt to Equity0.11Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 12, 2026
EPS Estimate
-$0.02
Consensus analyst estimate
Revenue Estimate
$12.41 M
Consensus analyst estimate

Next Earnings Call

Expected Date
March 17, 2027
EPS Estimate
-$0.04
Consensus analyst estimate
Revenue Estimate
$12.85 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.39, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.3929▼ 26.01%
Total Calls39,200▼ 83.35%
Total Puts15,400▼ 89.98%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %15.23%▼ 3.12%
Total Invested$33.61M▼ 1.74%
Investors Holding64▼ 46.00%

About Protalix BioTherapeutics Inc.

CEO: Dror Bashan

Protalix BioTherapeutics Insider Information FAQ

Stockcircle tracks 4 top investors with a current 13F position in Protalix BioTherapeutics. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.